StockData
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc. (OVID) stock

OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.26+0.04 (+1.80%)

Close on Nov 18, 2026Market cap $441.37MP/E –Yield –

Ovid Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Ovid Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$58.36M. For fiscal 2025 it was -$42.44M. The highest annual figure on record is $124.21M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$42.44M–
FY2024Dec 31, 2024-$61.89M–
FY2023Dec 31, 2023-$59.28M–
FY2022Dec 31, 2022-$55.55M-144.7%
FY2021Dec 31, 2021$124.21M–
FY2020Dec 31, 2020-$81.43M–
FY2019Dec 31, 2019-$61.41M–
FY2018Dec 31, 2018-$52.93M–
FY2017Dec 31, 2017-$65.01M–
FY2016Dec 31, 2016-$22.54M–
FY2015Dec 31, 2015-$13.19M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$15.70M–
Q1 FY2026Mar 31, 2026-$17.85M–
Q4 FY2025Dec 31, 2025-$12.29M–
Q3 FY2025Sep 30, 2025-$12.52M–
Q2 FY2025Jun 30, 2025-$5.07M–
Q1 FY2025Mar 31, 2025-$12.55M–
Q4 FY2024Dec 31, 2024-$10.72M–
Q3 FY2024Sep 30, 2024-$13.23M–
Q2 FY2024Jun 30, 2024-$20.52M–
Q1 FY2024Mar 31, 2024-$17.42M–
Q4 FY2023Dec 31, 2023-$18.19M–
Q3 FY2023Sep 30, 2023-$12.03M–
Q2 FY2023Jun 30, 2023-$14.17M–
Q1 FY2023Mar 31, 2023-$14.89M–
Q4 FY2022Dec 31, 2022-$12.17M–
Q3 FY2022Sep 30, 2022-$12.80M–
Q2 FY2022Jun 30, 2022-$14.30M–
Q1 FY2022Mar 31, 2022-$16.27M-109.2%
Q4 FY2021Dec 31, 2021-$26.35M–
Q3 FY2021Sep 30, 2021-$11.68M–
Q2 FY2021Jun 30, 2021-$14.31M–
Q1 FY2021Mar 31, 2021$176.56M–
Q4 FY2020Dec 31, 2020-$21.59M–
Q3 FY2020Sep 30, 2020-$16.40M–
Q2 FY2020Jun 30, 2020-$23.14M–
Q1 FY2020Mar 31, 2020-$20.29M–
Q4 FY2019Dec 31, 2019-$17.27M–
Q3 FY2019Sep 30, 2019-$16.77M–
Q2 FY2019Jun 30, 2019-$13.32M–
Q1 FY2019Mar 31, 2019-$14.05M–
Q4 FY2018Dec 31, 2018-$13.13M–
Q3 FY2018Sep 30, 2018-$13.18M–
Q2 FY2018Jun 30, 2018-$13.21M–
Q1 FY2018Mar 31, 2018-$13.43M–
Q4 FY2017Dec 31, 2017-$11.05M–
Q3 FY2017Sep 30, 2017-$9.41M–
Q2 FY2017Jun 30, 2017-$10.29M–
Q1 FY2017Mar 31, 2017-$34.26M–
Q4 FY2016Dec 31, 2016-$7.59M–
Q3 FY2016Sep 30, 2016-$5.81M–

More Ovid Therapeutics figures

See a number that looks wrong?